OneAscent Investment Solutions LLC Acquires Shares of 11,295 Royalty Pharma PLC $RPRX

Key Points

• OneAscent Investment Solutions LLC acquired a new stake in Royalty Pharma PLC worth approximately $352,000 by purchasing 11,295 shares in the first quarter.
• Multiple institutional investors have also increased their holdings in Royalty Pharma, with Victory Capital Management Inc. leading with a **270.4% increase** in its position during the first quarter.
• Royalty Pharma recently announced a **quarterly dividend of $0.22 per share**, reflecting an annualized yield of 2.4%, with a payout ratio of 50.87%.

OneAscent Investment Solutions LLC bought a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,295 shares of the biopharmaceutical company's stock, valued at approximately $352,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Applied Finance Capital Management LLC lifted its stake in Royalty Pharma by 3.0% in the first quarter. Applied Finance Capital Management LLC now owns 11,265 shares of the biopharmaceutical company's stock valued at $351,000 after buying an additional 329 shares during the period. Nissay Asset Management Corp Japan ADV lifted its stake in Royalty Pharma by 0.7% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock valued at $1,238,000 after buying an additional 349 shares during the period. Sherbrooke Park Advisers LLC lifted its stake in Royalty Pharma by 1.1% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after buying an additional 380 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in Royalty Pharma by 76.4% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 414 shares during the period. Finally, Allworth Financial LP increased its holdings in shares of Royalty Pharma by 41.6% in the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 452 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on RPRX. Wall Street Zen upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Citigroup increased their price objective on Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, July 22nd. Finally, Morgan Stanley increased their price objective on Royalty Pharma from $51.00 to $54.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $48.00.

Royalty Pharma Stock Down 0.1%

Shares of NASDAQ RPRX traded down $0.0530 during trading hours on Tuesday, hitting $35.8670. The company had a trading volume of 855,851 shares, compared to its average volume of 4,346,832. The stock has a market capitalization of $20.92 billion, a P/E ratio of 20.74, a price-to-earnings-growth ratio of 2.37 and a beta of 0.55. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.74. Royalty Pharma PLC has a 1-year low of $24.05 and a 1-year high of $38.00. The firm's 50 day moving average is $36.02 and its 200-day moving average is $33.80.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%.The company had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. On average, analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, August 15th. Royalty Pharma's dividend payout ratio (DPR) is presently 50.87%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.